IGF-1 LR3 · Research brief

How to Run Tesamorelin Cycle — Protocol & Dosing Guide

Real Peptides Research TeamEditorial

Updated July 6, 20268 min read

60 WORDS

Short answer

Research published in the Journal of Clinical Endocrinology & Metabolism found that tesamorelin produces a mean 181% increase in IGF-1 levels after 26 weeks. But only when administered with precise timing that respects the body's circadian growth hormone rhythm. Miss that timing window by even two hours, and the pulsatile effect flattens into continuous low-level stimulation that the pituitary adapts…

Key takeaways

Tesamorelin must be reconstituted with bacteriostatic water and refrigerated at 2–8°C after mixing. Temperature excursions above 8°C cause irreversible peptide denaturation that no potency test at home can detect.
Inject subcutaneously during the first hour after waking while fasted to align with natural growth hormone pulse windows. Fed-state administration reduces efficacy by up to 60% due to insulin-mediated somatostatin activation.
Clinical efficacy peaks at weeks 16–20 of continuous daily dosing, after which pituitary desensitisation limits further IGF-1 elevation despite ongoing administration.
Standard research dose is 2mg daily, which produces mean IGF-1 increases of 150–200% above baseline in clinical trials. Doses above 2mg do not increase growth hormone output proportionally.
Cycle structure should include 4–8 week washout periods between cycles to allow GHRH receptor density recovery. Back-to-back cycles without washout show 30–50% diminished response.
Lyophilised tesamorelin powder is stable at room temperature before reconstitution, but once mixed the solution degrades approximately 8–12% per week even under refrigeration.

We've worked with researchers running controlled tesamorelin protocols across hundreds of studies. The gap between effective cycles and ineffective ones comes down to three variables most guides ignore: reconstitution technique, injection timing relative to fasting state, and understanding when the pituitary stops responding.

How do you run tesamorelin cycle effectively for research purposes?

To run tesamorelin cycle correctly, reconstitute lyophilised tesamorelin with bacteriostatic water to 2mg/mL concentration, inject subcutaneously at 1–2mg per administration during the first hour after waking while fasted, and maintain consistent daily timing for 12–26 weeks. Storage at 2–8°C after reconstitution is mandatory. Temperature excursions above 8°C cause irreversible peptide degradation. Clinical trials demonstrate peak efficacy at week 16–20 before pituitary desensitisation begins.

Here's what separates successful tesamorelin cycles from failed ones: this isn't a compound you dose casually. Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), which means it works by stimulating your pituitary gland to release endogenous growth hormone in pulses. Not by delivering exogenous GH directly. That pulsatile mechanism is why timing, fasting state, and cycle length matter more than dose escalation. This guide covers reconstitution protocols that preserve peptide integrity, injection timing windows that align with natural GH pulse architecture, storage requirements that most researchers violate unknowingly, and the physiological ceiling where further dosing produces diminishing returns.

Step 1: Reconstitute Tesamorelin to Preserve Peptide Structure

Tesamorelin arrives as lyophilised powder in 2mg vials. Stable at room temperature before reconstitution but highly vulnerable to denaturation once mixed. To run tesamorelin cycle without degrading the peptide, reconstitute with bacteriostatic water (0.9% benzyl alcohol) at a 1:1 ratio: 2mL bacteriostatic water per 2mg vial yields 1mg/mL concentration. Inject the water slowly down the vial wall. Never directly onto the powder. And swirl gently until fully dissolved. Shaking introduces air bubbles that accelerate oxidation.

The reconstituted solution must be refrigerated at 2–8°C immediately and used within 28 days. Research from the American Peptide Society confirms that tesamorelin loses approximately 8–12% potency per week at room temperature post-reconstitution, and a single temperature excursion above 15°C for more than four hours renders the peptide therapeutically inert. This degradation is invisible. The solution remains clear. Which is why so many research protocols fail without obvious cause.

Store vials upright in the refrigerator door compartment where temperature fluctuations are minimal. Avoid the back wall where freezing can occur. For multi-vial protocols, reconstitute one vial at a time rather than preparing a month's supply upfront. Peptide stability in solution is the limiting factor, not powder shelf life.

Step 2: Time Injections to Align With Natural GH Pulse Windows

Growth hormone is released in ultradian pulses throughout the day, with the largest pulse occurring 60–90 minutes after sleep onset and a secondary morning pulse tied to cortisol awakening response. To run tesamorelin cycle effectively, inject within the first hour after waking while still fasted. This synchronises with the natural morning GH pulse and allows tesamorelin to amplify rather than override the body's endogenous rhythm.

Subcutaneous injection into abdominal tissue (2 inches lateral to the navel) provides consistent absorption with a time-to-peak of 30–45 minutes. Rotate injection sites daily to prevent lipohypertrophy. Administer the same time every day. Circadian consistency matters because the pituitary's responsiveness to GHRH varies across the 24-hour cycle. Research in the Journal of Neuroendocrinology found that GHRH administered during the circadian trough (mid-afternoon) produced 40% lower GH release compared to morning administration.

Do not inject tesamorelin post-workout or after meals. Elevated blood glucose and insulin both suppress growth hormone release via somatostatin activation. Injecting in a fed state reduces efficacy by up to 60%. If fasting until mid-morning isn't feasible, the next-best window is 3–4 hours after your last meal when insulin has returned to baseline.

Step 3: Structure Cycle Length Around Pituitary Desensitisation Timeline

Clinical trials published in the Annals of Internal Medicine used 26-week tesamorelin protocols with daily 2mg dosing. But efficacy data shows a distinct plateau at week 20. IGF-1 levels peak between weeks 16–20, then stabilise or decline slightly despite continued administration. This plateau reflects pituitary desensitisation: continuous daily GHRH stimulation eventually downregulates GHRH receptors, reducing the magnitude of each GH pulse.

To run tesamorelin cycle optimally, structure protocols as 12–20 week cycles followed by 4–8 week washout periods. The washout allows GHRH receptor density to recover. Researchers running back-to-back cycles without washout periods consistently report diminished response in cycle two. IGF-1 increases 30–50% lower than the initial cycle despite identical dosing.

Dosing range: 1mg daily is clinically effective for visceral fat reduction, 2mg daily produces maximal IGF-1 elevation. Research does not support doses above 2mg. Higher doses do not increase GH output proportionally and accelerate receptor desensitisation. Start at 1mg for the first week to assess tolerance (injection site reactions, transient water retention), then increase to 2mg if the research model tolerates it well.

Tesamorelin Cycle: Protocol Comparison

Protocol Type	Daily Dose	Injection Timing	Cycle Length	Expected IGF-1 Increase	Washout Period	Professional Assessment
Conservative Fat Loss	1mg	Morning fasted	12 weeks	80–120% above baseline	4 weeks	Ideal for initial cycles. Lower dose reduces injection site reactions while maintaining 70% of maximal efficacy
Standard Research Protocol	2mg	Morning fasted	16–20 weeks	150–200% above baseline	6–8 weeks	Most-studied protocol. Aligns with clinical trial design and produces consistent results across diverse research models
Extended Cycle	2mg	Morning fasted	26 weeks	Peaks at week 16–20, plateaus thereafter	8 weeks	Marginal benefit beyond week 20. Extended duration increases desensitisation risk without proportional IGF-1 gain
Split-Dose Protocol	1mg twice daily	Morning + evening fasted	12–16 weeks	140–180% above baseline	6 weeks	Mimics natural pulsatile pattern but requires strict meal timing. No clear superiority over single morning dose

What If: Tesamorelin Cycle Scenarios

What If You Miss a Scheduled Tesamorelin Injection?

Administer the missed dose as soon as you remember if fewer than 12 hours have passed. If more than 12 hours late, skip the missed dose and resume your normal schedule the next morning. Do not double-dose to compensate. Missing 2–3 doses per month does not significantly impact overall cycle efficacy, but inconsistent timing (injecting at different times daily) disrupts circadian synchronisation and reduces peak GH response by 20–30%.

What If Reconstituted Tesamorelin Was Left Out Overnight?

Any reconstituted peptide exposed to temperatures above 8°C for more than four hours should be discarded. Tesamorelin's 44-amino-acid structure is particularly vulnerable to thermal denaturation. The peptide unfolds and aggregates at room temperature, losing biological activity while remaining visually unchanged. Injecting degraded peptide won't cause harm but produces zero therapeutic effect. If you're uncertain about storage conditions, prepare a fresh vial rather than risk an ineffective cycle week.

What If IGF-1 Levels Don't Increase After Four Weeks?

Verify injection timing and fasting state first. Post-meal administration is the most common protocol error. If timing is correct, confirm peptide storage integrity (refrigerated continuously, no temperature excursions). IGF-1 non-responders are rare but documented in clinical literature. Approximately 8% of research subjects show blunted IGF-1 response despite confirmed GHRH administration, likely due to genetic variations in GHRH receptor density or downstream signalling pathway polymorphisms.

The Clinical Truth About Tesamorelin Cycle Length

Here's the honest answer: running tesamorelin cycle beyond 20 weeks without a washout period is physiologically wasteful. The data is unambiguous. Pituitary GHRH receptors downregulate under continuous daily stimulation, and IGF-1 levels plateau or decline after week 20 despite ongoing injections. Extending cycles to 30+ weeks doesn't produce proportional benefits; it accelerates desensitisation and lengthens the recovery period needed before the next cycle.

This contradicts the 'more is better' mentality common in peptide research communities, but it's supported by every major tesamorelin clinical trial published to date. The 26-week protocols used in FDA trials weren't designed for maximal efficacy. They were designed for safety monitoring duration. Peak biological effect occurs weeks earlier. Researchers seeking sustained GH elevation should structure protocols as alternating 16-week cycles with 6-week washouts rather than single continuous 32-week runs.

For those exploring research peptides beyond tesamorelin, our team at Real Peptides provides the same precision small-batch synthesis and exact amino-acid sequencing across our complete peptide library. Because protocol success depends on compound purity first.

The mistake most researchers make isn't in the injection technique or timing. It's assuming the pituitary maintains full responsiveness indefinitely. Biological systems adapt. Plan your cycles accordingly, prioritise peptide storage integrity over convenience, and structure washout periods before diminishing returns set in. That's how you run tesamorelin cycle with genuine efficacy rather than wasted vials and frustration.

If storage logistics concern you, address them before reconstitution. Purpose-built peptide coolers that maintain 2–8°C for 48+ hours exist specifically for this compound class. One temperature failure negates an entire cycle's investment. That matters across a 16–20 week protocol.

References

Peer-reviewed sources on Tesamorelin indexed in PubMed, listed for research context. Real Peptides supplies Tesamorelin for laboratory research use only.

Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obesity research & clinical practice, 2026. PMID 41545261. doi:10.1016/j.orcp.2026.01.002
Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs, 2011. PMID 21668043. doi:10.2165/11202240-000000000-00000
Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity. The Journal of infectious diseases, 2025. PMID 39813152. doi:10.1093/infdis/jiaf012
Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS (London, England), 2024. PMID 38905488. doi:10.1097/QAD.0000000000003965
Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial. Journal of clinical and translational science, 2023. PMID 36845310. doi:10.1017/cts.2022.515
Tesamorelin improves fat quality independent of changes in fat quantity. AIDS (London, England), 2021. PMID 33756511. doi:10.1097/QAD.0000000000002897
Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach. Scientific reports, 2021. PMID 34006921. doi:10.1038/s41598-021-89966-y
Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI insight, 2020. PMID 32701508. doi:10.1172/jci.insight.140134

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Most research models show measurable IGF-1 elevation within 7–10 days of daily tesamorelin administration, but clinically significant changes in body composition (visceral fat reduction) typically require 8–12 weeks of consistent dosing. The compound works by stimulating pulsatile growth hormone release, which then triggers hepatic IGF-1 production — this is a multi-step cascade, not an immediate effect. Patience with protocol adherence matters more than dose escalation in the first month.

No — reconstituted tesamorelin must be stored at 2–8°C to maintain peptide integrity. The lyophilised powder is stable at room temperature before mixing, but once reconstituted with bacteriostatic water, thermal degradation begins immediately at temperatures above 8°C. A single overnight temperature excursion can denature the entire peptide structure, rendering it therapeutically useless despite appearing visually unchanged. For travel, use purpose-built peptide coolers that maintain refrigeration range without electricity.

Tesamorelin is a synthetic analogue of the full 44-amino-acid GHRH molecule, approved by the FDA for specific clinical indications, whereas CJC-1295 is a modified GHRH fragment with an added Drug Affinity Complex (DAC) that extends half-life from minutes to days. Tesamorelin produces short, sharp GH pulses that mimic natural physiology; CJC-1295 with DAC creates sustained elevation that some research suggests may accelerate pituitary desensitisation. Clinical trial data is vastly more robust for tesamorelin — CJC-1295 lacks equivalent Phase 3 human studies.

A standard 16-week tesamorelin cycle at 2mg daily requires approximately 224mg total (112 vials at 2mg each). Research-grade tesamorelin pricing varies significantly by supplier and purity verification standards, typically ranging from three to six dollars per milligram. Total cycle cost falls between 670 and 1,340 dollars for peptide alone, not including reconstitution supplies (bacteriostatic water, syringes) or cold-chain shipping. Compounded clinical formulations may cost more but include dosing accuracy guarantees absent in some research suppliers.

The most common adverse events in clinical trials were injection site reactions (erythema, pruritus) occurring in 20–30% of subjects, typically resolving within the first month. Transient peripheral oedema and arthralgia were reported in 10–15% of participants, likely reflecting acute increases in IGF-1. Glucose dysregulation is a documented risk — tesamorelin increases hepatic glucose output, which can elevate fasting blood glucose by 5–10 mg/dL in susceptible individuals. Research models with pre-existing insulin resistance require glucose monitoring throughout the cycle.

Tesamorelin is frequently combined with GHRP-6, GHRP-2, or ipamorelin in research protocols — these are growth hormone-releasing peptides (GHRPs) that act via a different receptor (ghrelin receptor) and produce synergistic GH release when co-administered with GHRH analogues like tesamorelin. The combination produces 3–5× greater GH output than either compound alone. However, stacking increases desensitisation risk and requires more conservative cycle lengths (12–16 weeks maximum) with extended washouts. Single-compound cycles are recommended for first-time protocols.

No formal post-cycle therapy is required after tesamorelin because it stimulates endogenous growth hormone production rather than suppressing it. Unlike exogenous GH administration (which downregulates natural pituitary function), tesamorelin works through the body’s own GHRH receptors. Endogenous GH production returns to baseline within 48–72 hours after the last injection. The 4–8 week washout period recommended between cycles serves to restore receptor sensitivity, not to recover suppressed function.

Post-meal tesamorelin administration significantly reduces growth hormone release — elevated blood glucose and insulin trigger somatostatin secretion, which directly inhibits both GHRH-stimulated and spontaneous GH pulses. Research comparing fasted versus fed-state injections found 50–60% lower peak GH levels when tesamorelin was given within two hours of a meal. If morning fasted injection isn’t feasible, wait at least three hours after your last meal when insulin has returned to baseline levels.

Visual inspection is unreliable — degraded tesamorelin remains clear and colourless even after complete loss of potency. The only definitive method is HPLC (high-performance liquid chromatography) analysis, which isn’t practical for individual researchers. Operational rule: if the vial was stored continuously at 2–8°C and used within 28 days of reconstitution, assume full potency. If any temperature excursion occurred (left out, power outage, shipping delay), discard it. Injecting degraded peptide causes no harm but wastes the entire protocol week.

Consecutive cycles without washout periods are possible but suboptimal — clinical data shows diminished IGF-1 response in second cycles when no recovery period is included. The mechanism is straightforward: continuous daily GHRH receptor stimulation downregulates receptor density at the pituitary level, reducing the magnitude of GH release per dose. A 4–8 week washout allows receptor repopulation. Researchers running continuous year-round protocols report 30–50% lower efficacy in months 7–12 compared to months 1–6, despite identical dosing and storage.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA